Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2024-200397

Published: 2024

Journal Articles

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul B. Koller, Mohamad Cherry, Jessica K. Altman, Benjamin Tomlinson, Namrata Sonia Chandhok, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6220–6221.

https://doi.org/10.1182/blood-2022-167759

Published: 2022

Journal Articles

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Naval Daver, Kyoo Hyung Lee, Brian A. Jonas, Martha L. Arellano, Chul W. Jung, Sang Kyun Sohn, Sung-Soo Yoon, Jeong-Ok Lee, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6197–6199.

https://doi.org/10.1182/blood-2022-167972

Published: 2022

Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 6498–6500.

https://doi.org/10.1182/blood-2022-163683

Published: 2022

Journal Articles

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Blood (2021) 138 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2021-146324

Published: 2021

Journal Articles

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Blood (2021) 138 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2021-146003

Published: 2021

Journal Articles

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

Blood (2020) 136 (Supplement 1): 48–50.

https://doi.org/10.1182/blood-2020-138391

Published: 2020

Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

Holger W Auner, MD PhD, Maria Gavriatopoulou, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Meletios A Dimopoulos, Irina Kryachok, Professor, Halyna Pylypenko, MD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria Mateos, MD PhD, Michele Cavo, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137303

Published: 2020

Journal Articles

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-137574

Published: 2020

Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

Shambavi Richard, MD, Ajai Chari, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, Hua Chang, PhD, Yosef Landesman, PhD, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Sebastian Grosicki, MD PhD, Paul G. Richardson, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-137154

Published: 2020

Journal Articles

Novel R41Q- and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke

Ranjeet Kumar Sinha, PhD MSc, Yaoming Wang, PhD, Zhen Zhao, PhD, Jose A. Fernandez, MD PhD, Naveen Gupta, Xiao Xu, MSc, Greg Martin, MSc, Sergey Kupriyanov, PhD MSc, Laurent O Mosnier, PhD, Berislav Zlokovic, PhD, John H. Griffin, PhD

Blood (2016) 128 (22): 13.

https://doi.org/10.1182/blood.V128.22.13.13

Published: 2016

Journal Articles

Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells

Ranjeet Kumar Sinha, PhD MSc, Ryan P Flynn, PhD, Jose A. Fernandez, MD PhD, Xiao Xu, MSc, Greg Martin, MSc, Sergey Kupriyanov, PhD MSc, John H. Griffin, PhD, Bruce R. Blazar, MD

Blood (2016) 128 (22): 808.

https://doi.org/10.1182/blood.V128.22.808.808

Published: 2016

Journal Articles

Exome Genotyping Links Venous Thrombosis Risk with the Skeletal Muscle Myosin Gene Cluster and Leads to Discovery of New Family of Procoagulant Factors

Hiroshi Deguchi, MD PhD, Ranjeet Kumar Sinha, PhD MSc, Darlene J. Elias, MD, John H. Griffin, PhD

Blood (2015) 126 (23): 763.

https://doi.org/10.1182/blood.V126.23.763.763

Published: 2015

Journal Articles

Plasma Constitutive Serum Amyloid A4 Is Procoagulant and Is Elevated in Venous Thrombosis Patients

John H. Griffin, PhD, Jose A. Fernandez, MD PhD, Ranjeet Kumar Sinha, PhD MSc, Darlene J. Elias, MD, Hiroshi Deguchi, MD PhD

Blood (2015) 126 (23): 3486.

https://doi.org/10.1182/blood.V126.23.3486.3486

Published: 2015

Journal Articles

Novel R41Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for in Vivo Mechanisms of Action for Thrombin (IIa) and Activated Protein C (APC)

Ranjeet Kumar Sinha, PhD, Laurent Burnier, PhD, Naveen Gupta, MD, Xiao Xu, MS, Sergey Kupriyanov, PhD, Greg Martin, MS, Laurent O. Mosnier, PhD, John H. Griffin, PhD

Blood (2014) 124 (21): 99.

https://doi.org/10.1182/blood.V124.21.99.99

Published: 2014

Journal Articles

Activated Protein C Cytoprotective Signaling in Endothelial Cells Involves apoER2 and Disabled-1

Ranjeet Kumar Sinha, PhD, Xia Yang, PhD, Laurent O. Mosnier, PhD, John H. Griffin, PhD

Blood (2012) 120 (21): 1102.

https://doi.org/10.1182/blood.V120.21.1102.1102

Published: 2012

Journal Articles

Protection Against Vascular Leakage in Vivo by a Peptide Mimetic of the Novel Tethered Ligand Generated by Non-Canonical Cleavage of Protease Activated Receptor 1 by Activated Protein C

Laurent Burnier, PhD, Ranjeet Kumar Sinha, PhD, Eveline A. Bouwens, PhD, John H. Griffin, PhD, Laurent O. Mosnier, PhD

Blood (2012) 120 (21): 497.

https://doi.org/10.1182/blood.V120.21.497.497

Published: 2012

Journal Articles

Similar Survival after Bone Marrow Versus Peripheral Blood Stem Cell Transplantation from Matched Unrelated Donors in Children with Hematologic Malignancies.

Roland Meisel, MD, Hans-Juergen Laws, MD, Stephan Balzer, MD, Benedikt Bernbeck, MD, Christof Kramm, MD, Stephan Schoenberger, MD, Kumar Sinha, MD, Anja Troeger, MD, Peter Wernet, MD, Ulrich Goebel, MD, Juergen Enczmann, PhD, Dagmar Dilloo, MD

Blood (2005) 106 (11): 2066.

https://doi.org/10.1182/blood.V106.11.2066.2066

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

Novel R41Q- and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke

Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells

Exome Genotyping Links Venous Thrombosis Risk with the Skeletal Muscle Myosin Gene Cluster and Leads to Discovery of New Family of Procoagulant Factors

Plasma Constitutive Serum Amyloid A4 Is Procoagulant and Is Elevated in Venous Thrombosis Patients

Novel R41Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for in Vivo Mechanisms of Action for Thrombin (IIa) and Activated Protein C (APC)

Activated Protein C Cytoprotective Signaling in Endothelial Cells Involves apoER2 and Disabled-1

Protection Against Vascular Leakage in Vivo by a Peptide Mimetic of the Novel Tethered Ligand Generated by Non-Canonical Cleavage of Protease Activated Receptor 1 by Activated Protein C

Similar Survival after Bone Marrow Versus Peripheral Blood Stem Cell Transplantation from Matched Unrelated Donors in Children with Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only